Markers | 180-day mortality | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | HRa | 95 % CI | p | Sensitivity | 95 % CI | Specificity | 95 % CI | ROC-AUC | 95 % CI | p |
PTX3 | 1.05 | 0.47–2.35 | 0.902 | 0.69 | 0.53–0.82 | 0.56 | 0.50–0.60 | 0.66 | 0.56–0.76 | 0.005 |
PTX3b | 1.34 | 0.60–3.00 | 0.480 | 0.67 | 0.51–0.80 | 0.68 | 0.62–0.72 | . | . | . |
PCT | 0.86 | 0.38–1.95 | 0.713 | 0.66 | 0.50–0.79 | 0.55 | 0.49–0.60 | 0.65 | 0.55–0.76 | 0.007 |
CRP | 0.71 | 0.34–1.51 | 0.376 | 0.34 | 0.21–0.50 | 0.41 | 0.36–0.47 | 0.32 | 0.21–0.43 | 0.001 |
PTX3 + PCT | . | . | . | . | . | . | . | 0.66 | 0.56–0.76 | 0.005 |
PTX3 + CRP | . | . | . | . | . | . | . | 0.72 | 0.61–0.82 | <0.0001 |
PCT + CRP | . | . | . | . | . | . | . | 0.71 | 0.60–0.82 | <0.0001 |
PTX3 + PCT + CRP | . | . | . | . | . | . | . | 0.72 | 0.62–0.83 | <0.0001 |